Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q1 EPS of ($0.39), $0.82 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $62.5 million versus the consensus estimate of $172.97 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.